All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Molecular Research With Benign, Self-Limiting Bone Lesion May Unlock New Treatment Avenues for RAS/MAPK-Activated Tumors

August 29th 2025

R. Lor Randall, MD, FACS, spreads awareness about the benign, self-correcting nature of non-ossifying fibromas, which are commonly confused with sarcoma.

Perioperative Pembrolizumab/Sacituzumab Govitecan May Provide Effective Alternative to Cystectomy in MIBC

August 29th 2025

Andrea Necchi, MD, discusses how initial findings from the SURE-02 study indicate the potential for bladder preservation over cystectomy in MIBC.

Novel Tool Helps Identify Key Targets to Strengthen CAR NK Cell Therapies

August 29th 2025

Researchers have developed the first genome-wide CRISPR screening tool for primary human natural killer cells.

ADX-2191 Scores Orphan Designation in Europe for Primary LBCL of Immune-Privileged Sites

August 29th 2025

The EMA granted orphan designation to ADX-2191 for the management of LBCL of immune-privileged sites, including primary vitreoretinal lymphoma.

First-Line Anlotinib Plus Chemo Approved in China for Advanced Soft Tissue Sarcoma

August 29th 2025

The combination of anlotinib plus chemotherapy has been approved in China for the treatment of patients with advanced soft tissue sarcoma.

Sonrotoclax Hits Primary End Point in Phase 1/2 Trial of Relapsed/Refractory MCL

August 29th 2025

A phase 1/2 trial met its primary end point of ORR with sonrotoclax in patients with relapsed/refractory MCL.

FDA Approves 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer

August 29th 2025

The FDA has approved a 3-month version of leuprolide mesylate for patients with advanced prostate cancer.

Multidisciplinary Teams Tailor Therapies to Reduce Surgical Burden in Breast Cancer

August 29th 2025

Tari A. King, MD, FACS, FSSO, FASCO, discusses the importance of multidisciplinary breast cancer management and the potential to de-escalate treatment.

FDA’s Push for Faster Drug Reviews Intersects With Policy Shifts on EU-Imposed Tariffs

August 29th 2025

As the FDA aims to reduce drug review times, the 15% tariff rate imposed on pharmaceuticals from Europe could affect drug access in the oncology space.

Annamycin Plus Cytarabine Drive Potential OS Benefit in Acute Myeloid Leukemia

August 28th 2025

Annamycin plus cytarabine produced a potential overall survival benefit in acute myeloid leukemia.

Long-Term Outcomes Strengthen Role of Pola-R-CHP in Frontline DLBCL Management

August 28th 2025

Samina Hirani, MD, discusses the evolving first-line treatment paradigm for patients with DLBCL and the unprecedented findings from the POLARIX trial.

First-in-Concept ADC Micvotabart Pelidotin Shows Early Antitumor Activity in HNSCC

August 28th 2025

Glenn J. Hanna, MD, discusses the preliminary antitumor activity and safety profile of micvotabart pelidotin in head and neck squamous cell carcinoma.

Navigating Fixed-Duration vs Continuous Therapy Requires Strategic Sequencing in CLL

August 28th 2025

In an OncLive® Peer Exchange, 4 panelists discuss navigating fixed-duration vs continuous therapy in CLL.

FDA to Review Gedatolisib NDA in HR+/HER2–, PIK3CA Wild-Type Advanced Breast Cancer

August 28th 2025

The FDA has agreed to review an NDA submission for gedatolisib in hormone receptor–positive/HER2-negative, PIK3CA wild-type advanced breast cancer.

D3S-001 Receives FDA Breakthrough Therapy, Orphan Drug Designations in Select KRAS G12C-Mutant Solid Tumors

August 28th 2025

D3S-001 has received FDA breakthrough therapy and orphan drug designations in KRAS G12C-mutated NSCLC and CRC, respectively.

Some Breast Tumors Tunnel Into Fat to Fuel Up. Can We Stop Them?

August 28th 2025

UCSF researchers have discovered that the cells of triple-negative breast cancer tumors build molecular tunnels into nearby fat cells.

Experts Highlight Key Topics to Watch at the IASLC 2025 World Conference on Lung Cancer

August 28th 2025

Experts preview key abstracts to watch at the IASLC 2025 World Conference on Lung Cancer.

De-Escalated Surgical Strategies for Locoregional Breast Cancer Expand to Broader Populations

August 28th 2025

Tari A. King, MD, FACS, FSSO, FASCO, discusses locoregional breast cancer management strategies and avoiding lymph node dissection in select patients.

Daratumumab Plus KRd Offers a New Standard of Care in Newly Diagnosed Multiple Myeloma

August 27th 2025

C. Ola Landgren, MD, PhD, discusses the feasibility of daratumumab plus KRd as a standard of care for the management of newly diagnosed multiple myeloma.

Palbociclib Demonstrates Disease Control in Advanced Chordoma Harboring p16, CDKN2A Loss

August 27th 2025

Palbociclib hit the primary end point of disease control in a phase 2 study of patients with advanced chordoma harboring p16 and/or CDKN2A loss.